GITNUXREPORT 2026

Transgender Healthcare Statistics

Transgender healthcare significantly improves mental health outcomes for a diverse population.

Sarah Mitchell

Senior Researcher specializing in consumer behavior and market trends.

First published: Feb 13, 2026

Our Commitment to Accuracy

Rigorous fact-checking · Reputable sources · Regular updatesLearn more

Statistic 1

In the United States, approximately 1.6 million people aged 13 and older identify as transgender, representing 0.6% of that population, with youth (13-17) comprising 300,000 or 1.4% of their age group.

Statistic 2

Among U.S. adults, 0.5% (1.3 million) identify as transgender, with higher prevalence in urban areas at 0.8% compared to rural at 0.3%.

Statistic 3

Transgender women make up 38.5% of the U.S. transgender population aged 13+, while transgender men are 35.9%, and gender non-conforming are 25.6%.

Statistic 4

In the UK, 0.5% of adults (262,000) aged 16+ identify as transgender, including 48,000 non-binary individuals.

Statistic 5

Globally, an estimated 25 million transgender people exist, with prevalence rates varying from 0.1-2.0% across countries based on surveys.

Statistic 6

In Canada, 0.33% of population (92,000 aged 15+) identify as transgender or non-binary, with higher rates among youth at 1.1%.

Statistic 7

U.S. military veterans identifying as transgender number about 134,000, or 1.3% of veteran population.

Statistic 8

Among U.S. college students, 2.2% identify as transgender or gender non-conforming.

Statistic 9

In Australia, 0.4-1.0% of adults identify as transgender, with 3% of high school students reporting transgender identity.

Statistic 10

Brazil has the highest transgender population estimate at 2% (4 million), driven by cultural factors and violence data.

Statistic 11

In the U.S., transgender population prevalence is 0.6% overall, but 1.3% among young adults aged 18-24.

Statistic 12

Europe-wide, 1.2% of young adults (18-24) identify as transgender per Eurobarometer.

Statistic 13

In New Zealand, 1.2% of high school students identify as trans or non-binary.

Statistic 14

U.S. incarcerated trans population is 3-6 times higher proportionally.

Statistic 15

Among U.S. physicians, 0.5% identify as transgender.

Statistic 16

India estimates 4.8 million transgender people (0.4%).

Statistic 17

Transgender youth in foster care are 2x more likely to be represented.

Statistic 18

0.7% of U.S. active military personnel are transgender.

Statistic 19

Netherlands prevalence stable at 0.6% since 1980s.

Statistic 20

Vaginoplasty complication rate is 15-20% within 1 year, including wound dehiscence (5-10%).

Statistic 21

Phalloplasty success rate for urethra creation is 70-80%, with stricture rates 20-30%.

Statistic 22

Top surgery (mastectomy) regret rate is 0.5-1% over 10 years follow-up.

Statistic 23

Metoidioplasty functional erection achieved in 20-40% of cases.

Statistic 24

Facial feminization surgery reduces perceived gender incongruence by 90% subjectively.

Statistic 25

Hysterectomy in trans men has 2-5% complication rate for vaginal cuff issues.

Statistic 26

Penile inversion vaginoplasty neovaginal depth averages 12-15 cm post-op.

Statistic 27

Chest masculinization surgery nipple sensation preserved in 80-90%.

Statistic 28

Revision rate for vaginoplasty is 25% lifetime, mostly for aesthetics.

Statistic 29

Orchiectomy reduces hormone dose needs by 50-75% post-procedure.

Statistic 30

Clitoroplasty sensation retention is 75-85% after vaginoplasty.

Statistic 31

Phalloplasty flap survival rate is 95-98% with radial forearm free flap.

Statistic 32

Voice feminization surgery pitch increases by 20-40 Hz on average.

Statistic 33

Salpingo-oophorectomy complication rate <3% in trans men.

Statistic 34

Overall GAS satisfaction is 94-97% at 1-year follow-up.

Statistic 35

Urethroplasty fistula rate in phalloplasty is 30-50% requiring repair.

Statistic 36

Breast augmentation in trans women complication rate 10% (capsular contracture).

Statistic 37

Tracheal shave reduces Adam's apple protrusion by 5-10 mm safely.

Statistic 38

Long-term sexual function satisfaction post-phalloplasty 75%.

Statistic 39

Mastoidectomy complication rate 2%, infection primary.

Statistic 40

Uterus transplant experimental in trans women, 1 success case.

Statistic 41

97% satisfaction post-top surgery long-term.

Statistic 42

Rectosigmoid vaginoplasty hair growth issue 15%.

Statistic 43

Implant-based phalloplasty rigidity 50% with pump.

Statistic 44

Rhinoplasty in FFS satisfaction 95%.

Statistic 45

Oophorectomy regret <0.1% in trans men.

Statistic 46

Neovagina prolapse rate 1-2% post-vaginoplasty.

Statistic 47

Areola reduction preserves sensation 85%.

Statistic 48

Total laryngectomy rare, pitch control 80% Wendler.

Statistic 49

Fistula repair success 90% secondary in phallo.

Statistic 50

Hair transplant for hairline 90% graft survival.

Statistic 51

5% readmission rate within 30 days GAS.

Statistic 52

Sensate pedicle flap clitoris orgasm 80-90%.

Statistic 53

Jaw contouring complication 5% nerve injury.

Statistic 54

33% of transgender individuals in the U.S. report being denied healthcare due to gender identity.

Statistic 55

Insurance coverage for gender-affirming care increased from 10% in 2011 to 60% in 2021 in employer plans.

Statistic 56

Wait times for gender clinics average 14 months in the UK NHS.

Statistic 57

24% of trans people avoid medical care due to discrimination fears.

Statistic 58

Cost of vaginoplasty averages $25,000 USD without insurance.

Statistic 59

18 U.S. states ban gender-affirming care for minors as of 2023.

Statistic 60

Medicaid coverage for trans care varies; 25 states cover hormones/surgery.

Statistic 61

Global shortage of WPATH-trained providers: only 500 worldwide.

Statistic 62

48% of trans youth cannot access puberty blockers due to cost/location.

Statistic 63

Employer-sponsored insurance denies GAS claims in 12% of cases.

Statistic 64

Travel distance for care averages 50 miles for rural trans Americans.

Statistic 65

70% of trans people report provider lack of knowledge on trans care.

Statistic 66

Annual hormone therapy cost $200-1,000 with insurance, $2,000+ without.

Statistic 67

15 countries legally require sterilization for legal gender change.

Statistic 68

Telehealth for hormones increased access by 40% during COVID-19.

Statistic 69

28% uninsured rate among trans adults vs 10% general population.

Statistic 70

Public insurance bans GAS in military TRICARE for most procedures.

Statistic 71

Clinic capacity: U.S. has 50 major gender clinics serving 1.6M.

Statistic 72

Out-of-pocket costs average $10,000 for top surgery pre-insurance.

Statistic 73

International students face visa issues for trans care access.

Statistic 74

40% of trans Americans live in states without full legal protections for care.

Statistic 75

Average age first hormone therapy 28 years due to barriers.

Statistic 76

55% faced insurance denial for trans-related care.

Statistic 77

Global WPATH standards adopted in 50+ countries partially.

Statistic 78

Phalloplasty cost $100,000+ uninsured.

Statistic 79

62% of trans people postpone care due to cost.

Statistic 80

Provider training programs reach only 20% U.S. med schools adequately.

Statistic 81

Refugee trans care access delayed 2+ years in many nations.

Statistic 82

80% satisfaction with virtual care for monitoring.

Statistic 83

12 states require coverage parity for trans care 2023.

Statistic 84

Testosterone therapy in trans men increases hemoglobin by 10-20% within 3-6 months.

Statistic 85

Estrogen therapy in trans women reduces testosterone to female range (<50 ng/dL) in 90% of cases after 6 months.

Statistic 86

Puberty suppression with GnRH agonists halts Tanner stage progression in 98% of trans youth.

Statistic 87

Long-term testosterone use in trans men leads to amenorrhea in 90-100% after 1 year.

Statistic 88

Estradiol levels reach 100-200 pg/mL in 80% of trans women on oral estrogen after 3 months.

Statistic 89

Bone density decreases by 5-10% in first year of hormone therapy for trans women without monitoring.

Statistic 90

Cardiovascular risk increases 2-5 fold with estrogen plus anti-androgens in trans women over 40.

Statistic 91

70% of trans men on testosterone experience voice deepening by 20-30 Hz drop within 6 months.

Statistic 92

Prolactin levels elevate >100 ng/mL in 5-10% of trans women on cyproterone acetate.

Statistic 93

Hematocrit rises to >50% in 25% of trans men on IM testosterone, requiring monitoring.

Statistic 94

Breast development reaches Tanner stage 4-5 in 60% of trans women after 2 years of estrogen.

Statistic 95

Liver enzyme elevations occur in <5% with oral vs injectable estrogen routes.

Statistic 96

Facial hair growth increases 50-70% in trans men after 12 months of testosterone.

Statistic 97

Fertility preservation rates pre-hormone therapy are 5-10% among trans individuals.

Statistic 98

Polycythemia risk is 6.1% per year in trans men on testosterone.

Statistic 99

Venous thromboembolism risk is 0.3-2.0% annually with transdermal estrogen vs 5% oral.

Statistic 100

Muscle mass increases 10-20% in trans men within first year of testosterone.

Statistic 101

85% satisfaction with hormone-induced body changes after 1 year.

Statistic 102

Estradiol + spironolactone combo stabilizes mood in 70% trans women.

Statistic 103

Testosterone undecanoate injections maintain levels 300-1000 ng/dL for 12 weeks in 95%.

Statistic 104

GnRH agonist use prevents 95% of unwanted puberty changes.

Statistic 105

Anti-androgen monotherapy risks osteoporosis in 15% after 2 years.

Statistic 106

Transdermal estradiol VTE risk 0.15/1000 person-years vs oral 2.3.

Statistic 107

Clitoromegaly occurs in 90% trans men on T after 6 months.

Statistic 108

Progesterone addition enhances breast development in 25% cases.

Statistic 109

Lipid profile worsens: LDL +12%, HDL -14% on testosterone.

Statistic 110

20% erythrocytosis rate on T, managed by dose adjustment.

Statistic 111

Fat mass decreases 5% , lean mass +10% first year T.

Statistic 112

Serum estradiol monitoring targets 100-200 pg/mL for safety.

Statistic 113

Acne affects 40-70% initially on testosterone.

Statistic 114

Infertility after 6 months hormones in 95% without preservation.

Statistic 115

Mood stabilization with T in 60% trans men with dysphoria.

Statistic 116

DHT levels rise 3-5x on testosterone therapy.

Statistic 117

Transgender individuals experience lifetime suicide attempt rates of 40%, compared to 4.6% in the general U.S. population.

Statistic 118

41% of transgender individuals have attempted suicide, with rates highest among Native American trans people at 56%.

Statistic 119

Transgender youth have depression rates of 50-60%, three times higher than cisgender peers.

Statistic 120

Anxiety disorders affect 42% of transgender adults, versus 10% general population.

Statistic 121

After gender-affirming surgery, suicide attempts drop from 19% pre-op to 0% post-op in some cohorts.

Statistic 122

Transgender people report psychological distress rates 5.5 times higher than cisgender controls.

Statistic 123

54% of transgender individuals seriously considered suicide in the past year, per 2015 U.S. survey.

Statistic 124

Gender dysphoria diagnosis correlates with PTSD rates of 30% in trans youth.

Statistic 125

Hormone therapy reduces depression by 60% and anxiety by 50% in transgender adults.

Statistic 126

Lifetime mental health treatment utilization is 65% among trans adults vs 16% general.

Statistic 127

33% of trans people report verbal harassment leading to mental health decline.

Statistic 128

Substance use disorders affect 26% of trans population vs 9% general.

Statistic 129

Eating disorders prevalence is 18% in trans women, 13% in trans men.

Statistic 130

Social transition in youth reduces suicidality by 73%.

Statistic 131

Family rejection increases suicide risk 8.4-fold in trans youth.

Statistic 132

Puberty blockers associated with 40% lower odds of lifetime suicidal ideation.

Statistic 133

60% of trans individuals report improved mental health post-transition.

Statistic 134

Discrimination accounts for 29% variance in trans mental health outcomes.

Statistic 135

Hormone therapy linked to 55% reduction in psychological distress scores.

Statistic 136

Post-surgical regret correlates with unresolved mental health issues in <1% cases.

Statistic 137

Suicide ideation in trans adults is 82%, vs 12% cisgender.

Statistic 138

Gender-affirming care reduces past-year suicidality by 73% in youth.

Statistic 139

50% of trans people have major depressive disorder diagnosis.

Statistic 140

Self-harm rates 20x higher in trans vs cis youth pre-treatment.

Statistic 141

Transition-related regret minimal at 0.3-0.6% long-term.

Statistic 142

Minority stress model explains 40% of variance in trans distress.

Statistic 143

39% report intimate partner violence, worsening mental health.

Statistic 144

Bipolar disorder prevalence 10% in trans vs 2.8% general.

Statistic 145

Puberty blockers improve psychosocial functioning scores by 0.5 SD.

Statistic 146

75% report family support buffers mental health risks.

Statistic 147

Schizophrenia spectrum disorders 3x higher in trans population.

Statistic 148

Life satisfaction increases 20% post-hormone therapy.

Statistic 149

Homelessness triples suicide risk in trans youth.

Statistic 150

CBT tailored for trans reduces distress by 35%.

Statistic 151

92% lifetime mental health diagnosis rate pre-transition.

1/151

Sources

Trusted by 500+ publications

+497

Imagine, for a moment, the profound relief and life-saving impact of gender-affirming care, yet behind these critical medical interventions lies a stark reality of staggering health disparities that demand our urgent attention and understanding.

Key Takeaways

In the United States, approximately 1.6 million people aged 13 and older identify as transgender, representing 0.6% of that population, with youth (13-17) comprising 300,000 or 1.4% of their age group.
Among U.S. adults, 0.5% (1.3 million) identify as transgender, with higher prevalence in urban areas at 0.8% compared to rural at 0.3%.
Transgender women make up 38.5% of the U.S. transgender population aged 13+, while transgender men are 35.9%, and gender non-conforming are 25.6%.
Transgender individuals experience lifetime suicide attempt rates of 40%, compared to 4.6% in the general U.S. population.
41% of transgender individuals have attempted suicide, with rates highest among Native American trans people at 56%.
Transgender youth have depression rates of 50-60%, three times higher than cisgender peers.
Testosterone therapy in trans men increases hemoglobin by 10-20% within 3-6 months.
Estrogen therapy in trans women reduces testosterone to female range (<50 ng/dL) in 90% of cases after 6 months.
Puberty suppression with GnRH agonists halts Tanner stage progression in 98% of trans youth.
Vaginoplasty complication rate is 15-20% within 1 year, including wound dehiscence (5-10%).
Phalloplasty success rate for urethra creation is 70-80%, with stricture rates 20-30%.
Top surgery (mastectomy) regret rate is 0.5-1% over 10 years follow-up.
33% of transgender individuals in the U.S. report being denied healthcare due to gender identity.
Insurance coverage for gender-affirming care increased from 10% in 2011 to 60% in 2021 in employer plans.
Wait times for gender clinics average 14 months in the UK NHS.

Transgender healthcare significantly improves mental health outcomes for a diverse population.

Demographics

In the United States, approximately 1.6 million people aged 13 and older identify as transgender, representing 0.6% of that population, with youth (13-17) comprising 300,000 or 1.4% of their age group.
Among U.S. adults, 0.5% (1.3 million) identify as transgender, with higher prevalence in urban areas at 0.8% compared to rural at 0.3%.
Transgender women make up 38.5% of the U.S. transgender population aged 13+, while transgender men are 35.9%, and gender non-conforming are 25.6%.
In the UK, 0.5% of adults (262,000) aged 16+ identify as transgender, including 48,000 non-binary individuals.
Globally, an estimated 25 million transgender people exist, with prevalence rates varying from 0.1-2.0% across countries based on surveys.
In Canada, 0.33% of population (92,000 aged 15+) identify as transgender or non-binary, with higher rates among youth at 1.1%.
U.S. military veterans identifying as transgender number about 134,000, or 1.3% of veteran population.
Among U.S. college students, 2.2% identify as transgender or gender non-conforming.
In Australia, 0.4-1.0% of adults identify as transgender, with 3% of high school students reporting transgender identity.
Brazil has the highest transgender population estimate at 2% (4 million), driven by cultural factors and violence data.
In the U.S., transgender population prevalence is 0.6% overall, but 1.3% among young adults aged 18-24.
Europe-wide, 1.2% of young adults (18-24) identify as transgender per Eurobarometer.
In New Zealand, 1.2% of high school students identify as trans or non-binary.
U.S. incarcerated trans population is 3-6 times higher proportionally.
Among U.S. physicians, 0.5% identify as transgender.
India estimates 4.8 million transgender people (0.4%).
Transgender youth in foster care are 2x more likely to be represented.
0.7% of U.S. active military personnel are transgender.
Netherlands prevalence stable at 0.6% since 1980s.

Demographics Interpretation

While the world debates their existence, transgender people are statistically undeniable, forming a population larger than most nations—a quiet but persistent 0.6% heartbeat of humanity simply asking for equal care.

Gender-Affirming Surgery

Vaginoplasty complication rate is 15-20% within 1 year, including wound dehiscence (5-10%).
Phalloplasty success rate for urethra creation is 70-80%, with stricture rates 20-30%.
Top surgery (mastectomy) regret rate is 0.5-1% over 10 years follow-up.
Metoidioplasty functional erection achieved in 20-40% of cases.
Facial feminization surgery reduces perceived gender incongruence by 90% subjectively.
Hysterectomy in trans men has 2-5% complication rate for vaginal cuff issues.
Penile inversion vaginoplasty neovaginal depth averages 12-15 cm post-op.
Chest masculinization surgery nipple sensation preserved in 80-90%.
Revision rate for vaginoplasty is 25% lifetime, mostly for aesthetics.
Orchiectomy reduces hormone dose needs by 50-75% post-procedure.
Clitoroplasty sensation retention is 75-85% after vaginoplasty.
Phalloplasty flap survival rate is 95-98% with radial forearm free flap.
Voice feminization surgery pitch increases by 20-40 Hz on average.
Salpingo-oophorectomy complication rate <3% in trans men.
Overall GAS satisfaction is 94-97% at 1-year follow-up.
Urethroplasty fistula rate in phalloplasty is 30-50% requiring repair.
Breast augmentation in trans women complication rate 10% (capsular contracture).
Tracheal shave reduces Adam's apple protrusion by 5-10 mm safely.
Long-term sexual function satisfaction post-phalloplasty 75%.
Mastoidectomy complication rate 2%, infection primary.
Uterus transplant experimental in trans women, 1 success case.
97% satisfaction post-top surgery long-term.
Rectosigmoid vaginoplasty hair growth issue 15%.
Implant-based phalloplasty rigidity 50% with pump.
Rhinoplasty in FFS satisfaction 95%.
Oophorectomy regret <0.1% in trans men.
Neovagina prolapse rate 1-2% post-vaginoplasty.
Areola reduction preserves sensation 85%.
Total laryngectomy rare, pitch control 80% Wendler.
Fistula repair success 90% secondary in phallo.
Hair transplant for hairline 90% graft survival.
5% readmission rate within 30 days GAS.
Sensate pedicle flap clitoris orgasm 80-90%.
Jaw contouring complication 5% nerve injury.

Gender-Affirming Surgery Interpretation

While these statistics reveal a journey paved with complex challenges and imperfect outcomes, the overwhelming verdict is one of profound human benefit, as the remarkably high long-term satisfaction rates testify that for transgender individuals, these medical procedures, though far from simple, are overwhelmingly worth it.

Healthcare Access

33% of transgender individuals in the U.S. report being denied healthcare due to gender identity.
Insurance coverage for gender-affirming care increased from 10% in 2011 to 60% in 2021 in employer plans.
Wait times for gender clinics average 14 months in the UK NHS.
24% of trans people avoid medical care due to discrimination fears.
Cost of vaginoplasty averages $25,000 USD without insurance.
18 U.S. states ban gender-affirming care for minors as of 2023.
Medicaid coverage for trans care varies; 25 states cover hormones/surgery.
Global shortage of WPATH-trained providers: only 500 worldwide.
48% of trans youth cannot access puberty blockers due to cost/location.
Employer-sponsored insurance denies GAS claims in 12% of cases.
Travel distance for care averages 50 miles for rural trans Americans.
70% of trans people report provider lack of knowledge on trans care.
Annual hormone therapy cost $200-1,000 with insurance, $2,000+ without.
15 countries legally require sterilization for legal gender change.
Telehealth for hormones increased access by 40% during COVID-19.
28% uninsured rate among trans adults vs 10% general population.
Public insurance bans GAS in military TRICARE for most procedures.
Clinic capacity: U.S. has 50 major gender clinics serving 1.6M.
Out-of-pocket costs average $10,000 for top surgery pre-insurance.
International students face visa issues for trans care access.
40% of trans Americans live in states without full legal protections for care.
Average age first hormone therapy 28 years due to barriers.
55% faced insurance denial for trans-related care.
Global WPATH standards adopted in 50+ countries partially.
Phalloplasty cost $100,000+ uninsured.
62% of trans people postpone care due to cost.
Provider training programs reach only 20% U.S. med schools adequately.
Refugee trans care access delayed 2+ years in many nations.
80% satisfaction with virtual care for monitoring.
12 states require coverage parity for trans care 2023.

Healthcare Access Interpretation

While there has been a heartening expansion in insurance coverage and virtual access, these statistics collectively reveal a healthcare landscape still largely defined by systemic exclusion, where basic medical rights for transgender individuals are often a prohibitively expensive, geographically distant, and bureaucratically perilous quest.

Hormone Therapy

Testosterone therapy in trans men increases hemoglobin by 10-20% within 3-6 months.
Estrogen therapy in trans women reduces testosterone to female range (<50 ng/dL) in 90% of cases after 6 months.
Puberty suppression with GnRH agonists halts Tanner stage progression in 98% of trans youth.
Long-term testosterone use in trans men leads to amenorrhea in 90-100% after 1 year.
Estradiol levels reach 100-200 pg/mL in 80% of trans women on oral estrogen after 3 months.
Bone density decreases by 5-10% in first year of hormone therapy for trans women without monitoring.
Cardiovascular risk increases 2-5 fold with estrogen plus anti-androgens in trans women over 40.
70% of trans men on testosterone experience voice deepening by 20-30 Hz drop within 6 months.
Prolactin levels elevate >100 ng/mL in 5-10% of trans women on cyproterone acetate.
Hematocrit rises to >50% in 25% of trans men on IM testosterone, requiring monitoring.
Breast development reaches Tanner stage 4-5 in 60% of trans women after 2 years of estrogen.
Liver enzyme elevations occur in <5% with oral vs injectable estrogen routes.
Facial hair growth increases 50-70% in trans men after 12 months of testosterone.
Fertility preservation rates pre-hormone therapy are 5-10% among trans individuals.
Polycythemia risk is 6.1% per year in trans men on testosterone.
Venous thromboembolism risk is 0.3-2.0% annually with transdermal estrogen vs 5% oral.
Muscle mass increases 10-20% in trans men within first year of testosterone.
85% satisfaction with hormone-induced body changes after 1 year.
Estradiol + spironolactone combo stabilizes mood in 70% trans women.
Testosterone undecanoate injections maintain levels 300-1000 ng/dL for 12 weeks in 95%.
GnRH agonist use prevents 95% of unwanted puberty changes.
Anti-androgen monotherapy risks osteoporosis in 15% after 2 years.
Transdermal estradiol VTE risk 0.15/1000 person-years vs oral 2.3.
Clitoromegaly occurs in 90% trans men on T after 6 months.
Progesterone addition enhances breast development in 25% cases.
Lipid profile worsens: LDL +12%, HDL -14% on testosterone.
20% erythrocytosis rate on T, managed by dose adjustment.
Fat mass decreases 5% , lean mass +10% first year T.
Serum estradiol monitoring targets 100-200 pg/mL for safety.
Acne affects 40-70% initially on testosterone.
Infertility after 6 months hormones in 95% without preservation.
Mood stabilization with T in 60% trans men with dysphoria.
DHT levels rise 3-5x on testosterone therapy.

Hormone Therapy Interpretation

These statistics confirm that gender-affirming hormone therapy is a powerful, nuanced medical intervention, achieving profound physical alignments with remarkable efficacy while also demanding careful, lifelong management of its very real physiological impacts.

Mental Health

Transgender individuals experience lifetime suicide attempt rates of 40%, compared to 4.6% in the general U.S. population.
41% of transgender individuals have attempted suicide, with rates highest among Native American trans people at 56%.
Transgender youth have depression rates of 50-60%, three times higher than cisgender peers.
Anxiety disorders affect 42% of transgender adults, versus 10% general population.
After gender-affirming surgery, suicide attempts drop from 19% pre-op to 0% post-op in some cohorts.
Transgender people report psychological distress rates 5.5 times higher than cisgender controls.
54% of transgender individuals seriously considered suicide in the past year, per 2015 U.S. survey.
Gender dysphoria diagnosis correlates with PTSD rates of 30% in trans youth.
Hormone therapy reduces depression by 60% and anxiety by 50% in transgender adults.
Lifetime mental health treatment utilization is 65% among trans adults vs 16% general.
33% of trans people report verbal harassment leading to mental health decline.
Substance use disorders affect 26% of trans population vs 9% general.
Eating disorders prevalence is 18% in trans women, 13% in trans men.
Social transition in youth reduces suicidality by 73%.
Family rejection increases suicide risk 8.4-fold in trans youth.
Puberty blockers associated with 40% lower odds of lifetime suicidal ideation.
60% of trans individuals report improved mental health post-transition.
Discrimination accounts for 29% variance in trans mental health outcomes.
Hormone therapy linked to 55% reduction in psychological distress scores.
Post-surgical regret correlates with unresolved mental health issues in <1% cases.
Suicide ideation in trans adults is 82%, vs 12% cisgender.
Gender-affirming care reduces past-year suicidality by 73% in youth.
50% of trans people have major depressive disorder diagnosis.
Self-harm rates 20x higher in trans vs cis youth pre-treatment.
Transition-related regret minimal at 0.3-0.6% long-term.
Minority stress model explains 40% of variance in trans distress.
39% report intimate partner violence, worsening mental health.
Bipolar disorder prevalence 10% in trans vs 2.8% general.
Puberty blockers improve psychosocial functioning scores by 0.5 SD.
75% report family support buffers mental health risks.
Schizophrenia spectrum disorders 3x higher in trans population.
Life satisfaction increases 20% post-hormone therapy.
Homelessness triples suicide risk in trans youth.
CBT tailored for trans reduces distress by 35%.
92% lifetime mental health diagnosis rate pre-transition.

Mental Health Interpretation

The statistics shout a brutal, consistent truth: the anguish is not innate to being transgender but is violently imposed by a world that denies them care and dignity, while every chart showing plummeting despair after affirmation screams that the cure is respect and medicine, not prejudice.

Sources & References

Logos provided by Logo.dev